VEGFR2 Kinase Inhibitor III CAS: 204005-46-9
MF: C15H14N2O
MW: 238.28
A VEGFR2, Met, RET, PDGFR, and ALK inhibitor.

VEGFR2 Kinase Inhibitor III (CAS 204005-46-9)

VEGFR2 Kinase Inhibitor III | CAS 204005-46-9 is rated 5.0 out of 5 by 1.
  • y_2022, m_5, d_21, h_21
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.27
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202851, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 106ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Alternate Names: Semaxanib; SU 5416
Application: VEGFR2 Kinase Inhibitor III is a VEGFR2, Met, RET, PDGFR, and ALK inhibitor
CAS Number: 204005-46-9
Purity: ≥97%
Molecular Weight: 238.28
Molecular Formula: C15H14N2O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
loading

VEGFR2 Kinase Inhibitor III is a cell-permeable ATP-competitive inhibitor of Flk-1 (VEGFR2/KDR, kinase insert domain receptor), which is the major growth factor for vascular endothelial cells. This receptor is a type III tyrosine kinase receptor that functions as the main mediator of VEGF-induced endothelial proliferation, survival, and migration. Studies suggest that VEGFR2 Kinase Inhibitor III also inhibits a variety of other receptors such as Met, Flt-3/Flk-2 (FLT-3 receptor tyrosine kinases), Ret, c-Kit, PDGFR, c-Abl and Arg (ABL), and ALK. In addition, VEGFR2 kinase inhibitor III regulates the signaling pathways used by oncogenic RET-transfected cells by regulating the extracellular signal regulated kinase (ERK) and JNK pathways.


References

1. Vajkoczy, P., et al. 1999. Neoplasia. 1: 31-41. PMID: 10935468
2. Mologni, L., et al. 2006. J. Mol. Endocrinol. 37: 199-212. PMID: 17032739
3. Komi, Y., et al. 2009. Cancer Sci. 100: 269-277. PMID: 19200258

Physical State :
Solid
Solubility :
Soluble in DMSO (5 mg/ml), and ethanol (100 mM). Insoluble in water.
Storage :
Store at 4° C
Melting Point :
221-222° C
Boiling Point :
481.41° C at 760 mmHg (Predicted)
Density :
1.26 g/cm3 (Predicted)
Refractive Index :
n20D 1.68 (Predicted)
IC50 :
proliferation of HUVEC50s induced by VEGF: IC50 = 50 nM; autophosphorylation of internal tandem duplication: IC50 = 0.1 µM; autophosphorylation of wild type Fms-like tyrosine kinase 3: IC50 = 0.1 µM; VEGF-R: IC50 = 1.04 µM (NIH 3T3 cells overexpressing Flk-1); Oxytocin-R: EC5050 = 11.47 µM (human); AVP Receptor V1a: EC5050 = 12.07 µM (human); PDGF-R tyrosine kinases: IC50 = 20 µM (NIH 3T3 cells overexpressing Flk-1); proliferation of HUVEC50s induced by EC50GS: IC50 = 30.5 µM; proliferation of HUVEC50s induced by bFGF: IC50 = 5.3 µM
pK Values :
pKa: 13.18 (Predicted), pKb: 1.53 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
MDL Number :
MFCD01940922
SMILES :
CC1=CC(=C(N1)/C=C\\2/C3=CC=CC=C3NC2=O)C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

VEGFR2 Kinase Inhibitor III (CAS 204005-46-9)  Product Citations

See how others have used VEGFR2 Kinase Inhibitor III (CAS 204005-46-9). Click on the entry to view the PubMed entry .

Citations 1 to 6 of 6 total

PMID: # 26450128  Zhang, Y.|Wang, Y.|Lu, Q.|Xin, W.|Cui, W.|Zhu, J.| et al. 2016. Basic Clin Pharmacol Toxicol. 118: 259-70.

PMID: # 26699078  Giordano, A. et al. 2016. Vascul. Pharmacol. 80: 67-74.

PMID: # 25450973  Lahiani, A. et al. 2015. Biochim. Biophys. Acta. 1853: 422-30.

PMID: # 25886469  Cui, HJ. et al. 2015. BMC Complement Altern Med. 15: 91.

PMID: # 30028964  Chem Biol Interact. 110-120.

PMID: # 24751361  Giordano, A. et al. Vascul. Pharmacol. 61: 63-71.

Citations 1 to 6 of 6 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 92ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Lahiani Lahiani, et al. (PubMed ID 25450973) found that pre-treating mesenchymal stem cells with 240ng/ml of Semaxanib (VEGFR2 Kinase Inhibitor III) reduced the growth factors and co-culture conditioned medium effects by 70% and 20% respectively. -SCBT Publication Review
Date published: 2015-03-06
  • y_2022, m_5, d_21, h_21
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.27
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202851, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 15ms
  • REVIEWS, PRODUCT